Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±¾Ï ȯÀÚ¿¡¼­ º¹°­°æ°ñ¹Ý¸²ÇÁÀýÀýÁ¦¼úÀÇ Ãʱâ°æÇè Laparoscopic Pelvic Lymph Node Dissection in Patients with Prostate Cancer: the Early Experience

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 12È£ p.1236 ~ 1240
¼Ò¿µ¼®, ±èö¼º,
¼Ò¼Ó »ó¼¼Á¤º¸
¼Ò¿µ¼® (  ) 
Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ ¸¶Ãë°úÇб³½Ç

±èö¼º (  ) 
ºñ´¢±â°úÇб³½Ç

Abstract

¼­·Ð
ÀϹÝÀûÀ¸·Î Àü¸³¼±¾Ï ȯÀÚ¿¡¼­ °ñ¹Ý¸²ÇÁÀýÀüÀÌ°¡ ÀÖ´Â °æ¿ì´Â ÀüÀÌ°¡ ¾ø´Â °æ¿ìº¸´Ù ȯÀÚ
ÀÇ ¿¹ÈÄ°¡ ´õ ³ª»Ú¸ç ±ÙÄ¡Àû Àü¸³¼±ÀýÁ¦¼úÀÌ È¯ÀÚÀÇ »ýÁ¸À²À» Áõ°¡½ÃÅ°Áö ¸øÇϱ⠶§¹®¿¡ ¹æ
»ç¼± ¶Ç´Â È£¸£¸óÄ¡·á¸¦ ½ÃµµÇÑ´Ù. µû¶ó¼­ Àü¸³¼±¾Ï ȯÀÚ¿¡¼­ ¸²ÇÁÀýÀüÀÌ ¿©ºÎ´Â Ä¡·á¹æħ
ÀÇ °áÁ¤°ú ¿¹ÈÄ¿¡ Áö´ëÇÑ ¿µÇâÀ» ¹ÌÄ£´Ù.
Áö±Ý±îÁö °ñ¹Ý¸²ÇÁÀýÀüÀÌ ¿©ºÎ¸¦ È®ÀÎÇϱâ À§ÇÏ¿© CT³ª MRI°°Àº ºñħ½ÀÀûÀÎ ¹æ»ç¼±°Ë»ç
°¡ ½ÃÇàµÇ¾î¿ÔÀ¸³ª ¼ú Àü¿¡ ¸²ÇÁÀýÀüÀÌ ¿©ºÎ¸¦ Á¤È®ÇÏ°Ô ÆÇ´ÜÀ» Çϴµ¥ ÀÖ¾î ¹Î°¨µµ¿Í ƯÀÌ
µµ°¡ ³·Àº ¹®Á¦Á¡ÀÌ ÀÖ¾úÀ¸¸ç, °³º¹¼ö¼ú¿¡ ÀÇÇÑ °ñ¹Ý¸²ÇÁÀýÀýÁ¦¼úÀº °¡Àå Á¤È®ÇÑ ¹æ¹ýÀÌÁö
¸¸ ÇÕº´ÁõÀÇ ¹ß»ýÀ²ÀÌ ³ô°í ȯÀÚÀÇ ½É¸®Àû ºÎ´ãÀÌ Å©±â ¶§¹®¿¡ ±× À¯¿ë¼º¿¡ ÇÑ°è°¡ ÀÖ¾ú´Ù.
±×·¯³ª ºñ´¢±â°ú¿¡ º¹°­°æÀÌ µµÀԵǾî 1991³â Schuessler µîÀÌ º¹°­°æ°ñ¹Ý¸²ÇÁÀýÀýÁ¦¼ú¿¡
´ëÇÑ ÀÓ»ó°æÇèÀ» óÀ½ º¸°íÇÑ ÀÌ·¡ º¹°­°æ°ñ¹Ý¸²ÇÁÀýÀýÁ¦¼úÀº °üÇ÷Àû °ñ¹Ý¸²ÇÁÀýÀýÁ¦¼ú¿¡
ºñÇØ ºñ·Ï ¼ö¼ú½Ã°£ÀÌ ±æ°í Ä¡·áºñ°¡ ¸¹ÀÌ µå´Â ´ÜÁ¡ÀÌ ÀÖÀ¸³ª ÃâÇ÷·®ÀÌ Àû°í ¼ú ÈÄ µ¿ÅëÀÌ
Àû¾î ÁøÅëÁ¦ÀÇ Åõ¿©·®ÀÌ °¨¼ÒÇϸç ÀÔ¿ø±â°£ÀÌ Âª°í »çȸº¹±Í½Ã°£ÀÌ ºü¸¥ ÀåÁ¡ ¶§¹®¿¡ ¹Ì±¹
¿¡¼­´Â ºñ´¢±â°è º¹°­°æ ¼ö¼ú Áß °¡Àå ¸¹Àº ºóµµ¸¦ Â÷ÁöÇÏ°í ÀÖ´Ù. ±×·¯³ª ¿ì¸®³ª¶ó¿¡¼­´Â
ÀÌ µîÀÌ º¹°­°æ°ñ¹Ý¸²ÇÁÀýÀýÁ¦¼úÀ» óÀ½ º¸°íÇÑ ÀÌ·¡·Î ¾ÆÁ÷±îÁö º¸°íµÈ ¹Ù´Â ¾ø´Ù.
ÀúÀÚµéÀº 7·ÊÀÇ Àü¸³¼±¾Ï ȯÀÚ¿¡¼­ °ñ¹Ý¸²ÇÁÀýÀüÀÌ ¿©ºÎ¸¦ ÆľÇÇÏ¿© º´±â ¹× Ä¡·á¹æħÀ»
°áÁ¤ÇÏ°íÀÚ º¹°­°æ °ñ¹Ý¸²ÇÁÀýÀýÁ¦¼úÀ» ¼ú Àü Áø´Ü¸ñÀûÀ¸·Î ½ÃÇàÇÏ¿´±â¿¡ ÀÌÀÇ ÀÓ»óÀû È¿°ú
¸¦ ¹®Çå°íÂû°ú ÇÔ²² º¸°íÇÑ´Ù.
#ÃÊ·Ï#
Purpose : The status of the pelvic lymph node provides important information with
respect to the choice of therapy and prognosis in patients with prostate cancer. we
evaluated the clinical effectiveness and safety of laparoscopic pelvic lymph node
dissection in 7 patients with prostate cancer.
Materials and Methods : From July 1996 to December 1997, 7 patients whose mean age
was 67.7year (range 56-73) underwent transperitoneal laparoscopic pelvic lymph node
dissection as a staging procedure for prostatic cancer. We evaluated the clinical stage,
Gleason score, PSA, number of harvested lymph nodes, operative time, postoperative
hospital stay, and complications.
Results : Clinical stage was T1c-T2c, and mean Gleason score was 7.6(range 6-10).
Mean preoperative PSA was 35.3ng/ml(range 19-56.2). The mean number of removed
lymph nodes was 8.4(range 5-12) and lymph node metastases were noted in 2 patients.
Mean operative time was 180.7minutes (range 140-260). Mean postoperative hospital stay
was 2.1 days(range 2-3). Conversion from the laparoscopic procedure to open surgery
was not required. Subcutaneous emphysema occurred in 2 patients and was
conservatively managed.
Conclusions : Our preliminary experience suggests that laparoscopic pelvic lymph node
dissection could be performed safely and efficiently to detect the pelvic lymph node
metastasis in patients with prostate cancer with a short hospital stay and a low
morbidity, though being more time-consuming.

Å°¿öµå

Laparoscopy; Pelvic lymph node dissection; Prostate cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS